Part 1 of 2 — Havas (Trent University): Aires Defender Infinity Improves Cardiovascular Response During RFR Exposure
Double-Blind, Placebo-Controlled Case Study • Dr. Magda Havas, Trent University, Canada • August 18, 2015 • Subject: 52-year-old female with electrohypersensitivity
Two-Study Series by Dr. Magda Havas
① This Study (Aug 18, 2015)
52-year-old female with self-reported electrohypersensitivity. Double-blind, placebo-controlled. Cardiovascular improvements and live blood (rouleaux) improvements confirmed with shield vs. placebo.
② Part 2 (Aug 20, 2015)
46-year-old healthy female. Adds GDV Bio-Well energy field measurements (Dr. Korotkov technology). Cardiovascular improvements replicated; body energy balance also improved.
Report date: August 29, 2015 • Research conducted: August 18, 2015
Design: Double-blind, placebo-controlled (active Defender Infinity vs. placebo shield, subject blindfolded)
Study Design
Research was conducted in an electromagnetically clean environment (thick concrete walls, disconnected nearby Wi-Fi routers, GS filters installed, no visible cell towers). Background RFR was very low; when the 2.4 GHz cordless phone base station was activated, levels rose to approximately 120 mW/m² at the subject's chair.
The subject wore the shield or a placebo shield around the neck in a pouch. She was blinded to which treatment was active. Measurements were taken with an FDA Class II medical device (MaxPulse for cardiovascular), an FDA 510K HRV device (Nerve Express for orthostatic HRV), live blood microscopy, and standard blood pressure monitoring.
Confirmed: Shield Did Not Change the RF Environment
The Defender Infinity did not alter the amount of RFR in the environment, nor did it affect ELF electric or magnetic fields, dirty electricity, or body current. This is explicitly consistent with the manufacturer's claims. The protective mechanism operates on endogenous EM fields — the body's own electromagnetic response — not the external environment.
MaxPulse (FDA Class II): Cardiovascular Improvements with Shield, Reversed with Placebo
The subject's cardiovascular parameters improved in 10 ways with the shield during RFR exposure vs. reference. Key metrics:
• DPI (overall cardiovascular health): 15.9 (sub-optimal) → 28 (near-normal) with shield → 16.3 (sub-optimal) with placebo
• EC (eccentric constriction, vessel power from left ventricle): severe drop with placebo shield indicating severe reduction in vessel constriction ability
• AE (arterial elasticity): 34.4 (low-normal) → 65 (high-normal) with shield
The placebo-controlled design confirms these are not random variations — the shield drove the improvements.
Live Blood Analysis: Rouleaux Formation Reduced with Shield
Live blood analysis showed serious rouleaux formation (red blood cell aggregation). During treatment with the shield plus RFR exposure, rouleaux formation cleared up considerably. It became slightly worse again with the placebo shield and RFR. The improvement was attributable to the shield.
HRV and Subject Profile
The subject had exhausted adrenals and poor fitness score, consistent with chronic degenerative inflammation. HRV Tension Index (TI) approached normal during RFR with shield, then increased again with the placebo shield.
Conclusion (Author)
Dr. Havas concluded: "The claim that the Aires Defender Infinity 'protects' against RFR is confirmed based on cardiovascular parameters obtained via MaxPulse, by live blood analysis for rouleaux formation, and by the subjective response of test subject."
About Dr. Magda Havas
Dr. Magda Havas is a professor at Trent University (Peterborough, Ontario, Canada) in Environmental and Resource Studies. This 2015 research was commissioned by American Aires Inc. as independent third-party testing.